Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Jasper Therapeutics Inc. (JSPR)

Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 358,825
  • Shares Outstanding, K 15,064
  • Annual Sales, $ 0 K
  • Annual Income, $ -64,470 K
  • 60-Month Beta 2.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.74
Trade JSPR with:

Options Overview Details

View History
  • Implied Volatility 116.36% ( -0.48%)
  • Historical Volatility 71.33%
  • IV Percentile 32%
  • IV Rank 13.89%
  • IV High 722.53% on 12/19/23
  • IV Low 18.58% on 01/05/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 13
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 2,153
  • Open Int (30-Day) 2,061

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.20
  • Number of Estimates 3
  • High Estimate -1.16
  • Low Estimate -1.26
  • Prior Year -1.60
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.85 +5.90%
on 04/18/24
31.01 -25.38%
on 04/01/24
-1.72 (-6.92%)
since 03/18/24
3-Month
10.40 +122.39%
on 01/24/24
31.01 -25.38%
on 04/01/24
+10.99 (+90.45%)
since 01/18/24
52-Week
4.00 +478.50%
on 12/13/23
31.01 -25.38%
on 04/01/24
+8.74 (+60.69%)
since 04/18/23

Most Recent Stories

More News
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

GILD : 66.08 (-1.27%)
AMGN : 263.24 (-0.31%)
BMY : 48.09 (+0.52%)
NVS : 92.47 (-0.66%)
BGNE : 132.41 (+0.42%)
JSPR : 23.47 (-1.47%)
VIGL : 2.89 (-1.03%)
ALVR : 0.7350 (-2.89%)
RCUS : 14.83 (-0.07%)
FLACU : 9.50 (+2.48%)
CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel

CRISPR (CRSP) and Vertex complete BLA submissions to the FDA for exa-cel for treating sickle cell disease and transfusion-dependent beta-thalassemia.

VRTX : 393.67 (+0.15%)
CRSP : 57.93 (+4.27%)
KALA : 6.70 (-2.05%)
JSPR : 23.47 (-1.47%)
Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study

Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.

CRSP : 57.93 (+4.27%)
KALA : 6.70 (-2.05%)
KOD : 3.50 (-2.78%)
JSPR : 23.47 (-1.47%)
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis....

GSK : 39.17 (-1.09%)
NVO : 122.82 (-1.37%)
SCYX : 1.4400 (+1.41%)
JSPR : 23.47 (-1.47%)
Emergent's (EBS) Narcan Gets OTC Status for Opioid Overdose

Following the FDA approval, Emergent's (EBS) Narcan nasal spray becomes the first OTC product approved for emergency treatment of opioid overdose. This product will be made available by late summer of...

EBS : 1.9050 (+0.26%)
CRSP : 57.93 (+4.27%)
KALA : 6.70 (-2.05%)
JSPR : 23.47 (-1.47%)
Viking (VKTX) Announces Clinical Data for Metabolic Disorders

Viking (VKTX) announces positive clinical data, evaluating VK2735 to treat metabolic disorders. It is also initiating an early-stage extension study on the same.

NVO : 122.82 (-1.37%)
VKTX : 65.03 (-2.17%)
KALA : 6.70 (-2.05%)
JSPR : 23.47 (-1.47%)
Amicus (FOLD) Gets Pompe Disease Treatment Approval in Europe

Amicus (FOLD) receives approval from the European Commission to treat the adult late-onset Pompe disease with Pombiliti (cipaglucosidase alfa).

FOLD : 10.38 (-1.61%)
CRSP : 57.93 (+4.27%)
KALA : 6.70 (-2.05%)
JSPR : 23.47 (-1.47%)
Incyte's (INCY) Pemazyre Gets Approval to Treat MLNs in Japan

Incyte (INCY) receives approval for treating myeloid or lymphoid neoplasms using Pemazyre (pemigatinib) in Japan.

INCY : 52.55 (-0.32%)
CRSP : 57.93 (+4.27%)
KALA : 6.70 (-2.05%)
JSPR : 23.47 (-1.47%)
Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio

Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.

MRNA : 102.53 (-0.88%)
CRSP : 57.93 (+4.27%)
GBIO : 2.82 (-5.37%)
JSPR : 23.47 (-1.47%)
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders

Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.

CRSP : 57.93 (+4.27%)
BHVN : 42.74 (-2.93%)
KALA : 6.70 (-2.05%)
JSPR : 23.47 (-1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 25.64
2nd Resistance Point 25.09
1st Resistance Point 24.45
Last Price 23.47
1st Support Level 23.27
2nd Support Level 22.72
3rd Support Level 22.08

See More

52-Week High 31.01
Last Price 23.47
Fibonacci 61.8% 20.69
Fibonacci 50% 17.51
Fibonacci 38.2% 14.32
52-Week Low 4.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar